These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
659 related articles for article (PubMed ID: 12782601)
1. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Weber KL; Doucet M; Price JE; Baker C; Kim SJ; Fidler IJ Cancer Res; 2003 Jun; 63(11):2940-7. PubMed ID: 12782601 [TBL] [Abstract][Full Text] [Related]
2. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Kim SJ; Uehara H; Karashima T; Shepherd DL; Killion JJ; Fidler IJ Clin Cancer Res; 2003 Mar; 9(3):1200-10. PubMed ID: 12631626 [TBL] [Abstract][Full Text] [Related]
3. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Kim SJ; Uehara H; Yazici S; Langley RR; He J; Tsan R; Fan D; Killion JJ; Fidler IJ Cancer Res; 2004 Jun; 64(12):4201-8. PubMed ID: 15205332 [TBL] [Abstract][Full Text] [Related]
5. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591 [TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice. Yazici S; Kim SJ; Busby JE; He J; Thaker P; Yokoi K; Fan D; Fidler IJ Prostate; 2005 Nov; 65(3):203-15. PubMed ID: 15948138 [TBL] [Abstract][Full Text] [Related]
7. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer. Younes MN; Yazici YD; Kim S; Jasser SA; El-Naggar AK; Myers JN Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3425-34. PubMed ID: 16740767 [TBL] [Abstract][Full Text] [Related]
8. Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation. Younes MN; Yigitbasi OG; Park YW; Kim SJ; Jasser SA; Hawthorne VS; Yazici YD; Mandal M; Bekele BN; Bucana CD; Fidler IJ; Myers JN Cancer Res; 2005 Jun; 65(11):4716-27. PubMed ID: 15930290 [TBL] [Abstract][Full Text] [Related]
9. Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Yigitbasi OG; Younes MN; Doan D; Jasser SA; Schiff BA; Bucana CD; Bekele BN; Fidler IJ; Myers JN Cancer Res; 2004 Nov; 64(21):7977-84. PubMed ID: 15520205 [TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer. Onn A; Isobe T; Wu W; Itasaka S; Shintani T; Shibuya K; Kenji Y; O'reilly MS; Fidler IJ; Herbst RS Clin Cancer Res; 2004 Dec; 10(24):8613-9. PubMed ID: 15623645 [TBL] [Abstract][Full Text] [Related]
11. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Prewett M; Rothman M; Waksal H; Feldman M; Bander NH; Hicklin DJ Clin Cancer Res; 1998 Dec; 4(12):2957-66. PubMed ID: 9865906 [TBL] [Abstract][Full Text] [Related]
12. TGF-beta promotes the establishment of renal cell carcinoma bone metastasis. Kominsky SL; Doucet M; Brady K; Weber KL J Bone Miner Res; 2007 Jan; 22(1):37-44. PubMed ID: 17032147 [TBL] [Abstract][Full Text] [Related]
13. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. Lee LT; Huang YT; Hwang JJ; Lee PP; Ke FC; Nair MP; Kanadaswam C; Lee MT Anticancer Res; 2002; 22(3):1615-27. PubMed ID: 12168845 [TBL] [Abstract][Full Text] [Related]
14. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Kim SJ; Uehara H; Yazici S; He J; Langley RR; Mathew P; Fan D; Fidler IJ Cancer Res; 2005 May; 65(9):3707-15. PubMed ID: 15867366 [TBL] [Abstract][Full Text] [Related]
15. Renal cell carcinoma bone metastasis--elucidating the molecular targets. Weber K; Doucet M; Kominsky S Cancer Metastasis Rev; 2007 Dec; 26(3-4):691-704. PubMed ID: 17768599 [TBL] [Abstract][Full Text] [Related]
16. AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice. Park YW; Younes MN; Jasser SA; Yigitbasi OG; Zhou G; Bucana CD; Bekele BN; Myers JN Clin Cancer Res; 2005 Mar; 11(5):1963-73. PubMed ID: 15756022 [TBL] [Abstract][Full Text] [Related]
17. Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor. Harper ME; Goddard L; Glynne-Jones E; Assender J; Dutkowski CM; Barrow D; Dewhurst OL; Wakeling AE; Nicholson RI Prostate; 2002 Jun; 52(1):59-68. PubMed ID: 11992620 [TBL] [Abstract][Full Text] [Related]
18. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Radinsky R; Risin S; Fan D; Dong Z; Bielenberg D; Bucana CD; Fidler IJ Clin Cancer Res; 1995 Jan; 1(1):19-31. PubMed ID: 9815883 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Huang D; Ding Y; Luo WM; Bender S; Qian CN; Kort E; Zhang ZF; VandenBeldt K; Duesbery NS; Resau JH; Teh BT Cancer Res; 2008 Jan; 68(1):81-8. PubMed ID: 18172299 [TBL] [Abstract][Full Text] [Related]
20. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]